Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.72 |
| ▸ | CDK9 | P50750 | 9/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 7/20 | 0.72 |
| ▸ | GSK3B | P49841 | 2/20 | 0.72 |
| ▸ | GSK3A | P49840 | 1/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.58 |
| ▸ | CDK1 | P06493 | 5/20 | 0.54 |
| ▸ | CCNK | O75909 | 3/20 | 0.54 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CDK7 | P50613 | 2/20 | 0.54 |
| ▸ | CCNH | P51946 | 2/20 | 0.54 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19112253 | 0.91 | CDK2 (0.71) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19112174 | 0.88 | CDK2 (0.58) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19112176 | 0.87 | CDK2 (0.61) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL29326802 | 0.86 | CDK2 (0.56) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19139043 | 0.85 | CDK2 (0.75) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19112097 | 0.85 | CDK2 (0.75) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19111955 | 0.85 | CDK2 (0.75) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL3718719 | 0.84 | CDK2 (1.00) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL3718729 | 0.84 | CDK2 (1.00) | CDK2CCNA2CDK9CDK5CCNT1 | |
| SCHEMBL19112345 | 0.79 | CDK2 (0.57) | CDK2CCNA2CDK9CDK5CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| WO-2021214315-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | CDK2 1842/4885CCNA2 1833/4885CDK9 2449/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | CDK2 3765/4885CCNA2 3783/4885CDK9 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.